Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
KEYNOTE-B96 shows overall survival gains for pembrolizumab in platinum-resistant ovarian cancer. Find out why this trial could reshape treatment strategy.
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.
Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4
Merz Therapeutics files EMA application to expand XEOMIN for pediatric spasticity. Find out how this could shift the treatment landscape for cerebral palsy.
Bausch’s RED-C trial failed to meet endpoints in hepatic encephalopathy prevention. Find out what this means for rifaximin SSD’s future and the field.
Takeda Pharmaceutical Company Limited has reported positive topline results from two pivotal Phase 3 studies of its investigational drug zasocitinib (TAK-279), a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints, with more than 50 percent of participants achieving near-complete skin clearance (PASI
Innoviva Specialty Therapeutics has reported publication of pivotal Phase 3 data in The Lancet showing that its investigational oral antibiotic zoliflodacin was non-inferior to the current standard-of-care dual therapy for uncomplicated urogenital gonorrhea. The study, conducted in partnership with the Global Antibiotic Research & Development Partnership, or GARDP, compared a single oral dose of zoliflodacin
Eli Lilly and Company has announced successful topline results from its Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a triple hormone receptor agonist, in adults with obesity and knee osteoarthritis. The once-weekly investigational therapy delivered significant dual benefits: an average weight loss of 28.7 percent and a 75.8 percent reduction in joint pain, measured by